| Followers | 30 |
| Posts | 2112 |
| Boards Moderated | 0 |
| Alias Born | 01/02/2019 |
Wednesday, October 13, 2021 8:49:32 PM
When I watched the Linda Powers interview years ago I am still less than impressed. Let me put it in perspective for you......David Carr, first round draft for the Houston Texans for the 2001 season and beyond. What did he do? Nothing. Average to below at best. Fired him and moved on BUT he got paid the whole time. Even now when I look back at the 4 years I have been invested in this company, what has LP done? Hopefully something good. I remain positive however I am getting skeptical thus, my plan to exit November 9th without a PEEP of news. As I tell everyone on this board, do your own DD and decide. I have already posted the link several times. The more time over the roughly 300 day average for TLD and publication in a journal they get, (especially without absolutely any newszzz) the less support they will get. No news in October and they will be sub - dollar. That’s just the way it is and THEY KNOW THIS!!!! Enough said Pumpernickel!!!
Pumpernickel YuYU.....LaLAAAAA....YuLaYuLaYuuuuuuuuuuuuu........AAAAAAAAAAAAAAAAAAAAAAAAAWWWWWWWWWWWWWHHHHHHHHHHHHHOOOOOOOOOOOOOOOOOOOOeeeeeeeeeeeeeeeeeeeeeeeeeeeee!!!!!!!!!!!!
Pumpernickel YuYU.....LaLAAAAA....YuLaYuLaYuuuuuuuuuuuuu........AAAAAAAAAAAAAAAAAAAAAAAAAWWWWWWWWWWWWWHHHHHHHHHHHHHOOOOOOOOOOOOOOOOOOOOeeeeeeeeeeeeeeeeeeeeeeeeeeeee!!!!!!!!!!!!
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
